The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LEGN | -20% | +19.78% | +3.68% | -13% |
| S&P | +14.08% | +93.57% | +14.12% | +114% |
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.
Legend's cell therapy seems like it's a winner, but it might be priced in already.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $255.95M | 37.2% |
| Gross Profit | $151.74M | 16.1% |
| Gross Margin | 59.29% | -10.8% |
| Market Cap | $6.53B | -19.1% |
| Market Cap / Employee | $2.50M | 0.0% |
| Employees | 2.6K | 42.9% |
| Net Income | -$125.82M | -591.5% |
| EBITDA | -$16.08M | 56.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $266.66M | 32.2% |
| Accounts Receivable | $27.58M | 111.1% |
| Inventory | 35.6 | 88.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $382.01M | 13.8% |
| Short Term Debt | $5.91M | 77.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -18.69% | -3.4% |
| Return On Invested Capital | -35.81% | -25.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$28.93M | -38.0% |
| Operating Free Cash Flow | -$13.33M | -3257.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 7.70 | 5.35 | 5.99 | 6.42 | -7.47% |
| Price to Sales | 17.74 | 17.19 | 8.57 | 8.20 | -72.48% |
| Price to Tangible Book Value | 7.72 | 5.36 | 6.00 | 6.43 | -7.53% |
| Enterprise Value to EBITDA | -109.95 | -111.62 | -122.88 | -370.27 | 46.66% |
| Return on Equity | -28.4% | -15.5% | -20.0% | -29.7% | 33.75% |
| Total Debt | $346.59M | $350.60M | $362.81M | $387.92M | 14.46% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
